Roles of PDE1 in Pathological Cardiac Remodeling and Dysfunction

Overview

Journal J Cardiovasc Dev Dis

Specialty Cardiology & Vascular Diseases

Date 2018 Apr 26

PMID 29690591

Citations 14

Authors

Si Chen

Walter E Knight

Chen Yan

Affiliations

Soon will be listed here.

Abstract

Pathological cardiac hypertrophy and dysfunction is a response to various stress stimuli and can result in reduced cardiac output and heart failure. Cyclic nucleotide signaling regulates several cardiac functions including contractility, remodeling, and fibrosis. Cyclic nucleotide phosphodiesterases (PDEs), by catalyzing the hydrolysis of cyclic nucleotides, are critical in the homeostasis of intracellular cyclic nucleotide signaling and hold great therapeutic potential as drug targets. Recent studies have revealed that the inhibition of the PDE family member PDE1 plays a protective role in pathological cardiac remodeling and dysfunction by the modulation of distinct cyclic nucleotide signaling pathways. This review summarizes recent key findings regarding the roles of PDE1 in the cardiac system that can lead to a better understanding of its therapeutic potential.

Citing Articles

Mapping the glial transcriptome in Huntington's disease using snRNAseq: selective disruption of glial signatures across brain regions.

Bostrand S, Seeker L, Bestard-Cuche N, Kazakou N, Jakel S, Kenkhuis B Acta Neuropathol Commun. 2024; 12(1):165.

PMID: 39428482 PMC: 11492505. DOI: 10.1186/s40478-024-01871-3.

Demonstration of the Protective Effect of Vinpocetine in Diabetic Cardiomyopathy.

Erciyes D, Bora E, Tekindal M, Erbas O J Clin Med. 2024; 13(16).

PMID: 39200779 PMC: 11354616. DOI: 10.3390/jcm13164637.

Nanodomain cAMP signaling in cardiac pathophysiology: potential for developing targeted therapeutic interventions.

Zaccolo M, Kovanich D Physiol Rev. 2024; 105(2):541-591.

PMID: 39115424 PMC: 7617275. DOI: 10.1152/physrev.00013.2024.

Phosphodiesterase in heart and vessels: from physiology to diseases.

Fu Q, Wang Y, Yan C, Xiang Y Physiol Rev. 2023; 104(2):765-834.

PMID: 37971403 PMC: 11281825. DOI: 10.1152/physrev.00015.2023.

PDE10A Inactivation Prevents Doxorubicin-Induced Cardiotoxicity and Tumor Growth.

Chen S, Chen J, Du W, Mickelsen D, Shi H, Yu H Circ Res. 2023; 133(2):138-157.

PMID: 37232184 PMC: 10428174. DOI: 10.1161/CIRCRESAHA.122.322264.

References

Patrucco E, Domes K, Sbroggio M, Blaich A, Schlossmann J, Desch M . Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis. Proc Natl Acad Sci U S A. 2014; 111(35):12925-9. PMC: 4156763. DOI: 10.1073/pnas.1414364111. View

Lakics V, Karran E, Boess F . Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010; 59(6):367-74. DOI: 10.1016/j.neuropharm.2010.05.004. View

Cai Y, Knight W, Guo S, Li J, Knight P, Yan C . Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration. J Pharmacol Exp Ther. 2012; 343(2):479-88. PMC: 3477207. DOI: 10.1124/jpet.112.195446. View

Deb A, Ubil E . Cardiac fibroblast in development and wound healing. J Mol Cell Cardiol. 2014; 70:47-55. PMC: 4028446. DOI: 10.1016/j.yjmcc.2014.02.017. View

Das A, Xi L, Kukreja R . Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem. 2005; 280(13):12944-55. DOI: 10.1074/jbc.M404706200. View

Yan C, Zhao A, Bentley J, Beavo J . The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem. 1996; 271(41):25699-706. DOI: 10.1074/jbc.271.41.25699. View

Chan S, Yan C . PDE1 isozymes, key regulators of pathological vascular remodeling. Curr Opin Pharmacol. 2011; 11(6):720-4. PMC: 3225597. DOI: 10.1016/j.coph.2011.09.002. View

Das A, Durrant D, Salloum F, Xi L, Kukreja R . PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2014; 147:12-21. PMC: 4494657. DOI: 10.1016/j.pharmthera.2014.10.003. View

Cai Y, Li J, Yan C . Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Biochem Biophys Res Commun. 2013; 434(3):439-43. PMC: 3682500. DOI: 10.1016/j.bbrc.2013.03.092. View

10.

Yokoyama U, Patel H, Lai N, Aroonsakool N, Roth D, Insel P . The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. Proc Natl Acad Sci U S A. 2008; 105(17):6386-91. PMC: 2359804. DOI: 10.1073/pnas.0801490105. View

11.

McMullen J, Jennings G . Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol. 2007; 34(4):255-62. DOI: 10.1111/j.1440-1681.2007.04585.x. View

12.

Sonnenburg W, Seger D, KWAK K, Huang J, Charbonneau H, Beavo J . Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases. J Biol Chem. 1995; 270(52):30989-1000. DOI: 10.1074/jbc.270.52.30989. View

13.

Potter L . Guanylyl cyclase structure, function and regulation. Cell Signal. 2011; 23(12):1921-6. PMC: 4856045. DOI: 10.1016/j.cellsig.2011.09.001. View

14.

Maurice D, Ke H, Ahmad F, Wang Y, Chung J, Manganiello V . Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014; 13(4):290-314. PMC: 4155750. DOI: 10.1038/nrd4228. View

15.

Bonoczk P, Panczel G, Nagy Z . Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound. 2002; 15(1-2):85-91. DOI: 10.1016/s0929-8266(02)00006-x. View

16.

Buxton I, Duan D . Cyclic GMP/protein kinase G phosphorylation of Smad3 blocks transforming growth factor-beta-induced nuclear Smad translocation: a key antifibrogenic mechanism of atrial natriuretic peptide. Circ Res. 2008; 102(2):151-3. DOI: 10.1161/CIRCRESAHA.107.170217. View

17.

Hamad E, Zhu W, Chan T, Myers V, Gao E, Li X . Cardioprotection of controlled and cardiac-specific over-expression of A(2A)-adenosine receptor in the pressure overload. PLoS One. 2012; 7(7):e39919. PMC: 3391213. DOI: 10.1371/journal.pone.0039919. View

18.

Nagel D, Aizawa T, Jeon K, Liu W, Mohan A, Wei H . Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res. 2006; 98(6):777-84. PMC: 4114760. DOI: 10.1161/01.RES.0000215576.27615.fd. View

19.

Ding B, Abe J, Wei H, Huang Q, Walsh R, Molina C . Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation. 2005; 111(19):2469-2476. PMC: 4108189. DOI: 10.1161/01.CIR.0000165128.39715.87. View

20.

Ockaili R, Salloum F, Hawkins J, Kukreja R . Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol. 2002; 283(3):H1263-9. DOI: 10.1152/ajpheart.00324.2002. View